Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Percutaneous renal biopsy (PRB) is essential for the diagnosis, prognosis, and management of various kidney diseases. Bleeding is the most common complication associated with PRB. Although its incidence has markedly decreased with advances in technology, the risk remains clinically relevant. Balancing procedural success with minimizing bleeding complications remains an important challenge in nephrology practice.
This two-year retrospective study included 679 patients who underwent PRB between January 2022 and December 2023 at a tertiary hospital in southeast China. Continuous variables were analyzed using the Mann–Whitney test, while categorical variables were compared using the chi-square or Fisher’s exact test. Multivariate logistic regression analysis was applied to identify independent risk factors associated with post-biopsy hemorrhage.
Among 679 patients, post-biopsy bleeding occurred in 8.84% (60/679) of cases. A hemoglobin drop ≥20 g/L within 48 hours was observed in 4.86% (33/679), perirenal hematoma >5 cm requiring hemostatic medication in 4.27% (29/679), blood transfusion in 1.03% (7/679), and transcatheter embolization in 0.59% (4/679). Post-biopsy shock and mortality each occurred in 0.59% (4/679) and 0.29% (2/679), respectively. The incidence of bleeding varied across pathological subtypes, being highest in ANCA-associated vasculitis (12.00%), followed by diabetic nephropathy (10.34%), membranous nephropathy (10.00%), lupus nephritis (9.88%), and minimal change disease (8.33%). Multivariate analysis identified prolonged prothrombin time (PT) as an independent predictor of post-biopsy hemorrhage (OR = 2.326, 95% CI = 1.251–4.326).
The incidence of bleeding following PRB was 8.84% in this two-year cohort. Prolonged PT was significantly associated with an increased risk of post-biopsy hemorrhage. These findings highlight the importance of careful pre-procedural management, including discontinuation of anticoagulant or antiplatelet agents, routine monitoring of blood counts and coagulation profiles, and comprehensive risk assessment to minimize post-biopsy bleeding complications.
